Současné dvě EGFR mutace u plicního adenokarcinomu – kazuistika

English version

Autoři: M. Svaton ¹; M. Pesek ¹; Z. Chudacek ²; H. Vosmiková ³
Působiště autorů: Department of Pneumology, Charles University in Prague, Faculty of Medicine in Pilsen, University Hospital Pilsen, Czech Republic ¹; Department of Radiology, Charles University in Prague, Faculty of Medicine in Pilsen, University Hospital Pilsen, Czech Republic ²; Department of Pathology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Czech Republic ³
Vyšlo v časopise: Klin Onkol 2015; 28(2): 134-137
Kategorie: Kazuistika
doi: https://doi.org/10.14735/amko2015134

Souhrn

Cílená terapie pomocí EGFR‑ TKIs (epidermal growth factor receptor‑ tyrosine kinase inhibitors) je v současné době dobře zavedenou léčbou pro pacienty s tzv. častými EGFR mutacemi s pokročilým nebo metastatickým nemalobuněčným karcinomem plic. Účinnost této léčby pro tzv. vzácné a obzvláště pak pro tzv. komplexní EGFR mutace není zcela jasná. V naší kazuistice popisujeme případ 63leté ženy s metastatickým nemalobuněčným karcinomem plic s komplexní EGFR mutací (G719X + S768I), která byla léčena gefitinibem. Doba do progrese dosáhla osm měsíců. Následně diskutujeme naší kazuistiku s literárně zveřejněmými obdobnými případy. Celkově se zdá, že popisovaná komplexní mutace má relativně dobrou citlivost pro léčbu pomocí EGFR‑ TKIs.

Klíčová slova:
nemalobuněčný karcinom plic – EGFR gen – EGFR protein – complex mutations – rare EGFR mutations – EGFR‑ TKIs

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo:
24. 11. 2014

Přijato:
4. 2. 2015

Zdroje

1. Hsieh MH, Fang YF, Chang WC et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non‑small cell lung cancer. Lung Cancer 2006; 53(3): 311– 322.

2. Lund‑ Iversen M, Kleinberg L, Fjellbirkeland L et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR‑ exon 20 mutations. J Thorac Oncol 2012; 7(9): 1471– 1473. doi: 10.1097/ JTO.0b013e3182614a9d.

3. Fiala O, Pešek M, Fínek J et al. EGFR mutations in patients with advanced NSCLC. Klin Onkol 2012; 25(4): 267– 273. doi: 10.14735/ amko2012267.

4. Wu JY, Yu CJ, Chang YC et al. Effectiveness of tyrosine kinase inhibitors on „uncommon“ epidermal growth factor receptor mutations of unknown clinical significance in non‑small cell lung cancer. Clin Cancer Res 2011; 17(11): 3812– 3821. doi: 10.1158/ 1078‑ 0432.CCR‑ 10‑ 3408.

5. Svoboda M, Fabian P, Slaby O et al. EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review. Klin Onkol 2010; 23(4): 224– 230.

6. Tam IY, Leung EL, Tin VP et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009; 8(8): 2142– 2151. doi: 10.1158/ 1535‑ 7163.MCT‑ 08‑ 1219.

7. Heneberg P. Indication of EGFR kinase inhibitors should be refined. Klin Onkol 2011; 24(2): 87– 93.

8. Keam B, Kim DW, Park JH et al. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non‑small cell lung cancer. Int J Clin Oncol 2014; 19(4): 594– 600. doi: 10.1007/ s10147‑ 013‑ 0602‑ 1.

9. D‘Arcangelo M, D‘Incecco A, Cappuzzo F. Rare mutations in non‑small‑cell lung cancer. Future Oncol 2013; 9(5): 699– 711. doi: 10.2217/ fon.13.16.

10. Chen X, Zhu Q, Zhu L et al. Clinical perspective of afatinib in non‑small cell lung cancer. Lung Cancer 2013; 81(2): 155– 161. doi: 10.1016/ j.lungcan.2013.02.021.

11. Sharma A, Tan TH, Cheetham G et al. Rare and novel epidermal growth factor receptor mutations in non‑small‑cell lung cancer and lack of clinical response to gefitinib in two cases. J Thorac Oncol 2012; 7(5): 941– 942. doi: 10.1097/ JTO.0b013e31825134ac.

12. Watanabe S, Minegishi Y, Yoshizawa H et al. Effectiveness of gefitinib against non‑small‑cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol 2014; 9(2): 189– 194. doi: 10.1097/ JTO.0000000000000048.

13. Beau‑ Faller M, Prim N, Ruppert AM et al. Rare EGFR exon 18 and exon 20 mutations in non‑small‑cell lung cancer on 10 117 patients: a rarmulticentre observational study by the French ERMETIC‑ IFCT network. Ann Oncol 2014; 25(1): 126– 131. doi: 10.1093/ annonc/ mdt418.

14. Zhang GC, Lin JY, Wang Z et al. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non‑small cell lung cancer patients. Clin Oncol (R Coll Radiol) 2007; 19(7): 499– 506.

15. De Pas T, Toffalorio F, Manzotti M et al. Activity of epidermal growth factor receptor‑ tyrosine kinase inhibitors in patients with non‑small cell lung cancer-harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011; 6(11): 1895– 1901. doi: 10.1097/ JTO.0b013e318227e8c6.

16. Tam IY, Leung EL, Tin VP et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009; 8(8): 2142– 2151. doi: 10.1158/ 1535‑ 7163.MCT‑ 08‑ 1219.

17. Hata A, Yoshioka H, Fujita S et al. Complex mutations in the epidermal growth factor receptor gene in non‑small cell lung cancer. J Thorac Oncol 2010; 5(10): 1524– 1528. doi: 10.1097/ JTO.0b013e3181e8b3c5.

18. Doss GP, Rajith B, Chakraborty C et al. Structural signature of the G719S‑ T790M double mutation in the EGFR kinase domain and its response to inhibitors. Sci Rep 2014; 4: 5868. doi: 10.1038/ srep05868.

19. Kobayashi S, Canepa HM, Bailey AS et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013; 8(1): 45– 51. doi: 10.1097/ JTO.0b013e3182781e35.

20. Yokoyama T, Kondo M, Goto Y et al. EGFR point mutation in non‑small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 2006; 97(8): 753– 759.

21. Huang SF, Liu HP, Li LH et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non‑small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10(24): 8195– 8203.